EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Four weeks of romosozumab treatment increases trabecular bone volume and differentially improves cortical bone in young and aging mice with chronic kidney disease

Corinne E Metzger, Allison R Kolhouse, Joana Santamaria Vilchis, Samantha P Tippen, Landon Y Tak, Alec N LaPlant, Olivia N White, Joseph M Wallace, Matthew R Allen

Calcified Tissue International · 21.07.2026 · 117 (1)

DOI: 10.1007/s00223-026-01577-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Calcified Tissue International, online erschienen am 21.07.2026. Verfasst von Corinne E Metzger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomy Cell Biology and Physiology, Indiana University School of Medicine, 635 Barnhill Drive, MS 5045, Indianapolis, IN, 46202, USA. Hauptthemen laut MEDLINE: Cortical Bone, Renal Insufficiency, Chronic, Cancellous Bone, Aging. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, BLRD VA, U.S. Department of Veterans Affairs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD) leads to significant bone loss and high risk of fractures. Fractures are even more prevalent in the aging population with CKD. Cortical bone is particularly impacted in CKD due to cortical thinning and the development of cortical porosity. The goal of this study was to assess the impact of romosozumab, a bone anabolic therapy, on cortical bone in young and aging mice with adenine-induced CKD. Male C57Bl6/J mice, aged 16- and 66-weeks, were given 0.2% dietary adenine to induce CKD. Eight weeks after induction of CKD, a subset of young and aging adenine-CKD mice were given romosozumab (10 mg/kg, 1x/week for 4 weeks); the study also included age-matched healthy controls. At the study endpoint, all adenine-CKD mice had high blood urea nitrogen and parathyroid hormone compared to controls. Romosozumab-treated groups of both ages had higher trabecular bone volume due to increased trabecular thickness, indicating an anabolic effect of therapy. Romosozumab-treated young mice had higher midshaft femur cortical bone area and cortical thickness, but there were no differences in cortical porosity compared to untreated adenine. Aging mice had no differences in cortical thickness, but cortical pore number was lower with romosozumab treatment. Four-point-bending mechanical tests showed 20% higher ultimate force with romosozumab treatment in both ages, statistically different from untreated adenine in the young cohort. These data demonstrate positive cortical bone effects from four weeks of romosozumab treatment in both young and aging mice with established CKD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cortical BoneRenal Insufficiency, ChronicCancellous BoneAgingAntibodies, MonoclonalBone Density Conservation AgentsAnimalsMaleMiceMice, Inbred C57BLBone Density

Stichwörter der Autor:innen

AgingChronic kidney diseaseCortical porosityRomosozumab

Substanzen

romosozumabAntibodies, MonoclonalBone Density Conservation Agents

Autor:innen und Institutionen

  • Department of Anatomy Cell Biology and Physiology, Indiana University School of Medicine, 635 Barnhill Drive, MS 5045, Indianapolis, IN, 46202, USA.
  • Weldon School of Biomedical Engineering, Purdue University, Indianapolis, IN, 46202, USA.
  • Roudebush Veterans Administration Medical Center, Indianapolis, IN, 46202, USA.
  • Department of Anatomy Cell Biology and Physiology, Indiana University School of Medicine, 635 Barnhill Drive, MS 5045, Indianapolis, IN, 46202, USA. matallen@iu.edu.
  • Roudebush Veterans Administration Medical Center, Indianapolis, IN, 46202, USA. matallen@iu.edu.
  • Department of Medicine, Division of Nephrology, Indiana University School of Medicine, Indianapolis, IN, 46202, USA. matallen@iu.edu.

Förderung

  • NIDDK NIH HHS
  • BLRD VA
  • U.S. Department of Veterans Affairs
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Metzger, C. E., Kolhouse, A. R., Vilchis, J. S., Tippen, S. P., Tak, L. Y., LaPlant, A. N., White, O. N., Wallace, J. M., & Allen, M. R. (2026). Four weeks of romosozumab treatment increases trabecular bone volume and differentially improves cortical bone in young and aging mice with chronic kidney disease. Calcified Tissue International, 117(1). https://doi.org/10.1007/s00223-026-01577-9

Vancouver

Metzger CE, Kolhouse AR, Vilchis JS, Tippen SP, Tak LY, LaPlant AN, et al. Four weeks of romosozumab treatment increases trabecular bone volume and differentially improves cortical bone in young and aging mice with chronic kidney disease. Calcified Tissue International. 2026;117(1). doi:10.1007/s00223-026-01577-9

BibTeX
@article{Metzger2026,
  author = {Metzger, Corinne E and Kolhouse, Allison R and Vilchis, Joana Santamaria and Tippen, Samantha P and Tak, Landon Y and LaPlant, Alec N and White, Olivia N and Wallace, Joseph M and Allen, Matthew R},
  title = {Four weeks of romosozumab treatment increases trabecular bone volume and differentially improves cortical bone in young and aging mice with chronic kidney disease},
  journal = {Calcified Tissue International},
  year = {2026},
  volume = {117},
  number = {1},
  doi = {10.1007/s00223-026-01577-9}
}
Kostenlos starten →